{Reference Type}: Journal Article
{Title}: Toxoplasma gondii vaccine candidates: a concise review.
{Author}: Mamaghani AJ;Fathollahi A;Arab-Mazar Z;Kohansal K;Fathollahi M;Spotin A;Bashiri H;Bozorgomid A;
{Journal}: Ir J Med Sci
{Volume}: 192
{Issue}: 1
{Year}: Feb 2023
{Factor}: 2.089
{DOI}: 10.1007/s11845-022-02998-9
{Abstract}: Toxoplasma gondii is an obligate intracellular parasite that causes toxoplasmosis. It has been shown that the severity of symptoms depends on the functioning of the host immune system. Although T. gondii infection typically does not lead to severe disease in healthy people and after infection, it induces a stable immunity, but it can contribute to severe and even lethal Toxoplasmosis in immunocompromised individuals (AIDS, bone marrow transplant and neoplasia). The antigens that have been proposed to be used in vaccine candidate in various studies include surface antigens and secretory excretions that have been synthesized and evaluated in different studies. In some studies, secretory antigens play an important role in stimulating the host immune response. Various antigens such as SAG, GRA, ROP, ROM, and MAG have been from different strains of T. gondii have been synthesized and their protective effects have been evaluated in animal models in different vaccine platforms including recombinant antigens, nanoparticles, and DNA vaccine. Four bibliographic databases including Science Direct, PubMed Central (PMC), Scopus, and Google Scholar were searched for articles published up to 2020.The current review article focuses on recent studies on the use and usefulness of recombinant antigens, nanoparticles, and DNA vaccines.